Clinical trial

Ideal Imaging Time Point Assessment for Spinal Cord Lesions of Unknown Etiology With FDG PET-MRI

NCT04219969

Name

2018-0144

Description

To compare the results and understand the possible benefits from FDG-PET/MRI during different scanning time points after FDG, a type of contrast drug, is given.

Trial arms

Trial start

2018-09-21

Estimated PCD

2024-05-07

Trial end

2024-05-07

Status

Completed

Treatment

Fludeoxyglucose F-18

Given IV

Arms:

Diagnostic (18F-FDG PET-MRI)

Other names:

18FDG, FDG, Fludeoxyglucose (18F), fludeoxyglucose F 18, Fludeoxyglucose F18, Fluorine-18 2-Fluoro-2-deoxy-D-Glucose, Fluorodeoxyglucose F18

Magnetic Resonance Imaging

Undergo PET-MRI

Arms:

Diagnostic (18F-FDG PET-MRI)

Other names:

Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR Imaging, MRI, MRI Scan, NMR Imaging, NMRI, nuclear magnetic resonance imaging

Positron Emission Tomography

Undergo PET-MRI

Arms:

Diagnostic (18F-FDG PET-MRI)

Other names:

Medical Imaging, Positron Emission Tomography, PET, PET scan, Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging

Size

Primary endpoint

Standard uptake value (SUV) max

Up to 8 hours

Lesion to background (L/B) ratio

Up to 8 hours

Optimal imaging time point

Up to 8 hours

Eligibility criteria

Inclusion Criteria: * Patients with untreated intramedullary cord lesion(s) * Ability to undergo FDG PET MR examination Exclusion Criteria: * No prior surgery or biopsy of the spinal cord * No metal implanted in area of interest * Spine radiation therapy * Known allergy to FDG or gadolinium based contrast agents * Blood glucose (\> 200 mg/dl) * Pregnant women are excluded * Children of less than 18 years of age * Need for conscious sedation or anesthesia in order to tolerate study

Protocol

{'studyType': 'INTERVENTIONAL', 'phases': ['NA'], 'designInfo': {'allocation': 'NA', 'interventionModel': 'SINGLE_GROUP', 'primaryPurpose': 'DIAGNOSTIC', 'maskingInfo': {'masking': 'NONE'}}, 'enrollmentInfo': {'count': 11, 'type': 'ACTUAL'}}

Updated at

2024-05-09

1 organization

1 product

1 indication

Organization

M.D. Anderson Cancer Center

Product

Fludeoxyglucose F-18

Indication

Spinal Cord Tumor